Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease

References

• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–2149.
   PubMed Web of Science ®Google Scholar
• Petty R, Southwood T, Manners P, et al. International league of associations for rheumatology classification of juvenile arthritis: second revision. Arthritis Rheum. 2004;31(2):390–392.
   Google Scholar
• Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15(9):931–934.
   PubMed Web of Science ®Google Scholar
• Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12(1):56–59.
   PubMed Web of Science ®Google Scholar
• Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30(2):121–133.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still’s disease. Ann Rheum Dis. 2006;65(5): 564–572.
   PubMed Web of Science ®Google Scholar
• Fautrel B. Adult-onset Still disease. Best Practice and Research: Clinical Rheumatology. 2008;22(5):773–792.
   PubMed Web of Science ®Google Scholar
• Iglesias J, Sathiraju S, Marik PE. Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still’s disease: clinical response with high-dose pulse methylprednisolone therapy. Chest. 1999;115(6):1738–1740.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Kawaguchi Y, Tada Y, et al. Beneficial use of serum ferritin and heme oxygenase-1 as biomarkers in adult-onset Still’s disease: a multicenter retrospective study. Mod Rheumatol. 2018;28(5):858–864.
   PubMed Web of Science ®Google Scholar
• Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259–268.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Kadavath S, Mehta B. Life-threatening complications of adult-onset Still’s disease. Clin Rheumatol. 2014;33(3):305–314.
   PubMed Web of Science ®Google Scholar
• Ravelli A, De Benedetti F, Viola S, et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128(2):275–278.
   PubMed Web of Science ®Google Scholar
• Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106(4):561–566.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Yamamura M, Taniai M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease. Arthritis Rheum. 2001;44(3):550–560.
   PubMedGoogle Scholar
• Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferon-y, and tumor necrosis factor-a levels in patients with adult still’s disease. J Rheumatol. 1998;25(2):396–398.
   PubMed Web of Science ®Google Scholar
• Li S, Zheng S, Tang S, et al. Autoinflammatory pathogenesis and targeted therapy for adult-onset still’s disease. Clinical Reviews in Allergy and Immunology. 2020;58(1):71–81.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9:1157.
   PubMed Web of Science ®Google Scholar
• De Luca G, Cavalli G, Campochiaro C, et al. Myocarditis: an interleukin-1-mediated disease? Front Immunol. 2018;9:1335.
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–1486.
   PubMed Web of Science ®Google Scholar
• Fitzgerald AA, LeClercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 2005;52(6):1794–1803.
   PubMedGoogle Scholar
• Petryna O, Jack Cush J, Efthimiou P. IL-1 trap rilonacept in refractory adult onset Still’s disease. Ann Rheum. Dis. 2012;71(12):2056–7.2012.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, The IL-1. family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612–632.
   PubMed Web of Science ®Google Scholar
• Hsieh CW, Chen YM, Lin CC, et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease. J Rheumatol. 2017;44(8):1142–1150.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Farina N, Campochiaro C, et al. Current treatment options and safety considerations when treating adult-onset Still’s disease. Expert Opin Drug Saf. 2020;19(12):1549–1558.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Franchini S, Aiello P, et al. Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol. 2015;44(4):309–314.
   PubMed Web of Science ®Google Scholar
• Gopalarathinam R, Orlowsky E, Kesavalu R, et al. Adult onset still’s disease: a review on diagnostic workup and treatment options. Case Rep Rheumatol. 2016;2016:6502373.
   PubMedGoogle Scholar
• Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis. 2001;60(Suppl 3):iii55–7.
   PubMed Web of Science ®Google Scholar
• Zhou S, Qiao J, Bai J, et al. Biological therapy of traditional therapy-resistant adult-onset still’s disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167–171.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset still’s disease. J Rheumatol. 2004;31(11):2189–2198.
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–754.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–555.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Sota J, Ruscitti P, et al. The treatment of adult-onset Still’s disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clin Exp Rheumatol. 2021;39(1):187–195.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720–1729.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016 Sep;75(9):1654–1660.
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36(6):1118–1125.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Goldin NP, Wolff SM. Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med. 1974;139(6):1369–1381.
   PubMed Web of Science ®Google Scholar
• Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. Nat Immunol. 2016;17(8):906–913.
   PubMed Web of Science ®Google Scholar
• Andrei C, Dazzi C, Lotti L, et al. The secretory route of the leaderless protein interleukin 1β involves exocytosis of endolysosome-related vesicles. Mol Biol Cell. 1999;10(5):1463–1475.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Cenci S. Autophagy and protein secretion. J Mol Biol. 2020;432(8):2525–2545.
   PubMed Web of Science ®Google Scholar
• Günther S, Deredge D, Bowers AL, et al. IL-1 family cytokines use distinct molecular mechanisms to signal through their shared co-receptor. Immunity. 2017;47(3):510–523.e4.
   PubMed Web of Science ®Google Scholar
• Kastner DL, Aksentijevich I, Autoinflammatory disease G-MR. Reloaded: a clinical perspective. Cell. 2010;140(6):784–790.
   PubMed Web of Science ®Google Scholar
• Manthiram K, Zhou Q, Aksentijevich I, et al. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832–842.
   PubMed Web of Science ®Google Scholar
• Schett G, Dayer JM, Manger B. Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol. 2016;12(1):14–24.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatol (United Kingdom). 2015;54(12):2134–2144.
   PubMed Web of Science ®Google Scholar
• Klück V, Van Deuren RC, Cavalli G, et al. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Ann Rheum Dis. 2020;79(4):536–544.
   PubMed Web of Science ®Google Scholar
• Ballak DB, Li S, Cavalli G, et al. Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. J Biol Chem. 2018;293(37):14224–14236.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Koenders M, Kalabokis V, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatol (United Kingdom). 2016;56(12):2256.
   Web of Science ®Google Scholar
• Tomelleri A, Cavalli G, De Luca G, et al. Treating heart inflammation with interleukin-1 blockade in a case of erdheim-chester disease. Front Immunol. 2018;9:1233.
   PubMed Web of Science ®Google Scholar
• Alten R, Gram H, La J, et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R67.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378(20):1908–1919.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;206(5):1029–1036.
   Google Scholar
• Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–1848.
   PubMed Web of Science ®Google Scholar
• Sun H, Van LM, Floch D, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2016;56(12):1516–1527.
   PubMed Web of Science ®Google Scholar
• Rondeau JM, Ramage P, Zurini M, et al. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs. 2015;7(6):1151–1160.
   PubMed Web of Science ®Google Scholar
• Gram H. The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer. Pharmacol Res. 2020;154:104139.
   PubMed Web of Science ®Google Scholar
• Neubert RT, Webb JR, Neubert D. Feasibility of human trials to assess developmental immunotoxicity, and some comparison with data on new world monkeys. Human and Experimental Toxicology. 2002;21(9–10):543–567.
   PubMed Web of Science ®Google Scholar
• Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1–18.
   PubMedGoogle Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25): 2396–2406.
   PubMed Web of Science ®Google Scholar
• EMA. European medicines agency decision PIP. EMA/794178. 2015;(1901):1–10.
   Google Scholar
• Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018;77(12):1710–1719.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Quartier P, Alexeeva E, et al. Efficacy and safety of canakinumab in patients with systemic juvenile idiopathic arthritis with and without fever at baseline: results from an open‐label, active‐treatment extension study. Arthritis Rheumatol. 2020;72(12):2147–2158.
   PubMed Web of Science ®Google Scholar
• Quartier P, Alexeeva E, Tamàs C, et al. Tapering canakinumab monotherapy in patients with systemic juvenile idiopathic arthritis in clinical remission: results from an open‐label, randomized phase iIIb/IV study. Arthritis Rheumatol. 2021;73(2):336–346.
   PubMed Web of Science ®Google Scholar
• Maritsi DN, Vougiouka O, Eleftheriou D. Discontinuation of canakinumab following clinical disease remission is feasible in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2020;47(4):634–635.
   PubMed Web of Science ®Google Scholar
• Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset still’s disease. Semin Arthritis Rheum. 2012;42(2):201–205.
   PubMed Web of Science ®Google Scholar
• Chamseddin B, Marks E, Dominguez A, et al. Refractory macrophage activation syndrome in the setting of adult-onset Still disease with hemophagocytic lymphohistiocytosis detected on skin biopsy treated with canakinumab and tacrolimus. J Cutan Pathol. 2019;46(7):528–531.
   PubMed Web of Science ®Google Scholar
• Barsotti S, Neri R, Iacopetti V, et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol. 2014;20(2):121.
   PubMed Web of Science ®Google Scholar
• Vitale A, Berlengiero V, Sota J, et al. Real-life data on the efficacy of canakinumab in patients with adult-onset still’s disease. Mediators Inflamm. 2020;2020:8054961.
   PubMed Web of Science ®Google Scholar
• Banse C, Vittecoq O, Benhamou Y, et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still’s disease. Jt Bone Spine. 2013;80(6):653–655.
   PubMed Web of Science ®Google Scholar
• Lo Gullo A, Caruso A, Pipitone N, et al. Canakinumab in a case of adult onset Still’s disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81(4):376–377.
   PubMed Web of Science ®Google Scholar
• Eriksson P, Jacobs C, Söderkvist P. A patient with a phenotype of adult-onset still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. J Rheumatol. 2013;40(9):1632–1633.
   PubMed Web of Science ®Google Scholar
• Sinha A, Patti R, Ambesh P, et al. Severe pulmonary hypertension due to adult-onset still’s disease. J Investig Med High Impact Case Reports. 2018;6:2324709618757260.
   Web of Science ®Google Scholar
• Maria ATJ, Le Quellec A, Jorgensen C, et al. Adult onset still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13(11):1149–1159.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still’s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.
   PubMed Web of Science ®Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10(1):1–11.
   PubMedGoogle Scholar
• Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther. 2019;21(1):53.
   PubMedGoogle Scholar
• Cavalli G, Tomelleri A, De Luca G, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Therapy. 2019;21(1): 69.
   PubMedGoogle Scholar
• Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still’s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36(4):668–675.
   PubMed Web of Science ®Google Scholar
• Kedor C, Listing J, Zernicke J, et al. Canakinumab for treatment of adult-onset still’s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020;79(8):1090–1097.
   PubMed Web of Science ®Google Scholar
• Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331.
   PubMedGoogle Scholar
• Mehta P, Cron RQ, Hartwell J, et al. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2(6):e358–e367.
   PubMedGoogle Scholar
• Henter JI, Elinder G, Soder O, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918–2922.
   PubMed Web of Science ®Google Scholar
• Henter JI, Andersson B, Elinder G, et al. Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 1996;27(1):21–25.
   PubMedGoogle Scholar
• Stéphan JL, Koné-Paut I, Galambrun C, et al. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001;40(11):1285–1292.
   PubMed Web of Science ®Google Scholar
• Goda K, Kenzaka T, Hoshijima M, et al. Adult-onset Still’s disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling: a case-based review. Rheumatol Int. 2020;40(1):145–152.
   PubMed Web of Science ®Google Scholar
• Durand M, Troyanov Y, Laflamme P, et al. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37(4):879–880.
   PubMed Web of Science ®Google Scholar
• Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology. 2011;50(2):417–419.
   PubMed Web of Science ®Google Scholar
• Zeft A, Hollister R, Lafleur B, et al. Anakinra for systemic juvenile arthritis: the rocky mountain experience. J Clin Rheumatol. 2009;15(4):161–164.
   PubMed Web of Science ®Google Scholar
• Grom AA, Ilowite NT, Pascual V, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68(1):218–228.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Minoia F, Bohnsack J, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res. 2018;70(3):409–419.
   PubMed Web of Science ®Google Scholar
• Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160–3169.
   PubMed Web of Science ®Google Scholar
• Mellins ED, MacAubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7(7):416–426.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Foppoli M, Cabrini L, et al. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol. 2017;8:131.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Pappalardo F, Mangieri A, et al. Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med. 2016;44(8):e751–4.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Fallanca F, Dinarello CA, et al. Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med. 2015;191(5):596–598.
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Cavalli G, Farina N, et al. Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. Annals of the Rheumatic Diseases. 2019; annrheumdis-2019-216610
   Google Scholar
• De Luca G, Campochiaro C, Dinarello CA, et al. Treatment of dilated cardiomyopathy with interleukin-1 inhibition. Ann Intern Med. 2018;169(11):819–820.
   PubMed Web of Science ®Google Scholar
• Nigrovic PA. Is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405–1413.
   PubMed Web of Science ®Google Scholar
• Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset still’s disease and sepsis. J Rheumatol. 2010;37(11):2369–2376.
   PubMed Web of Science ®Google Scholar